UNASSIGNED: Alzheimer's ( @entity195 ) and @entity191 are @entity179 presently without effective drug treatments. @entity195 is characterized by general @entity73 , difficulties with memory consolidation and retrieval, and with advanced stages episodes of @entity2146 and anger. @entity195 is increasing in frequency as life expectancy increases. Present FDA approved medications do little to slow disease progression and none address the underlying progressive loss of synaptic connections and neurons. New drug design approaches are needed beyond cholinesterase inhibitors and @entity1024 receptor antagonists. @entity1 with @entity1726 experience the symptomatic triad of bradykinesis, @entity400 -at-rest, and @entity2003 with the possibility of additional non-motor symptoms including @entity25 , @entity308 , @entity303 , and @entity4148 . This review summarizes available information regarding the role of the brain renin-angiotensin system (RAS) in learning and memory and motor functions, with particular emphasis on research results suggesting a link between angiotensin IV (AngIV) interacting with the @entity50799 subtype. Currently there is controversy over the identity of this @entity50799 protein. Albiston and colleagues have offered convincing evidence that it is the @entity50799 ( @entity50799 ). Recently members of our laboratory have presented evidence that the brain AngIV/ @entity50799 system coincides with the brain hepatocyte growth factor/c-Met receptor system. In an effort to resolve this issue we have synthesized a number of small molecule AngIV-based compounds that are metabolically stable, penetrate the blood-brain barrier, and facilitate compromised memory and motor systems. These research efforts are described along with details concerning a recently synthesized molecule, Dihexa that shows promise in overcoming @entity2414 by augmenting synaptic connectivity via the formation of new functional synapses.

The development of small molecule angiotensin IV analogs to treat XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients'] @entity1024 :: ('CHEBI:31882', 'Chemical') :: ['N-methyl-d-aspartate'] @entity2003 :: ('MESH:D009127', 'Disease') :: ['rigidity'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression'] @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's (PD) diseases"] @entity1726 :: ('OMIM:168600', 'Disease') :: ['PD'] @entity400 :: ('MESH:D014202', 'Disease') :: ['tremor'] @entity2146 :: ('MESH:D011595', 'Disease') :: ['agitation'] @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative diseases'] @entity4148 :: ('MESH:D001342', 'Disease') :: ['autonomic nervous system failure'] @entity195 :: ('MESH:D000544', 'Disease') :: ['AD'] @entity50799 :: ('4012', 'Gene') :: ['insulin-regulated aminopeptidase', 'AT4 receptor', 'IRAP'] @entity2414 :: ('MESH:D008569', 'Disease') :: ['memory and motor dysfunctions'] @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disturbances']
@entity191 :: (MESH:D010300,Disease) :: ['Alzheimer's and Parkinson's diseases']
